Evidence map›Paper›PMID 34900859›Full record

ReviewFrontiers in pediatrics2021

Recent Advances in Kidney Bioengineering.

Nina Cintron Pregosin, Robert Bronstein, Sandeep K Mallipattu

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Nina Cintron PregosinDivision of Nephrology, Department of Medicine, Stony Brook University, Stony Brook, NY, United States.
Robert BronsteinDivision of Nephrology, Department of Medicine, Stony Brook University, Stony Brook, NY, United States.
Sandeep K MallipattuDivision of Nephrology, Department of Medicine, Stony Brook University, Stony Brook, NY, United States.
Stony Brook University · USNorthport VA Medical Center · US

Funding

Transcriptional control of mitochondrial function by KLF6 in diabetic kidney diseaseR01DK112984 · NIDDK · STATE UNIVERSITY NEW YORK STONY BROOK · PI Sandeep K Mallipattu · 2017 to 2026
$3.5M
Mechanisms mediating podocyte-parietal epithelial cell crosstalk in proliferative glomerulopathiesR01DK121846 · NIDDK · STATE UNIVERSITY NEW YORK STONY BROOK · PI HE, JOHN CIJIANG, MALLIPATTU, SANDEEP K · 2020 to 2024
$2.7M
BLRD VA I01 BX003698BLRD VA I01 BX005300NIDDK NIH HHS R01 DK112984NIDDK NIH HHS R01 DK121846
6 · The paper itself

Abstract

Kidney disease is an epidemic that affects more than 600 million people worldwide. The socioeconomic impacts of the disease disproportionately affect Hispanic and non-Hispanic Black Americans, making the disease an issue of social inequality. The urgency of this situation has only become worse during the COVID-19 pandemic, as those who are hospitalized for COVID-19 have an increased risk of kidney failure. For researchers, the kidney is a complex organ that is difficult to accurately model and understand. Traditional cell culture models are not adequate for studying the functional intricacies of the kidney, but recent experiments have offered improvements for understanding these systems. Recent progress includes organoid modeling, 3D bioprinting, decellularization, and microfluidics. Here, we offer a review of the most recent advances in kidney bioengineering.

Indexed as

3D bioprintingbioengineeringdecellularizationmicrofluidicsorganoidsorgan-on-a chip

Identifiers

PMID34900859
PMCPMC8655860
OpenAlexW3215359233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.